MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Molecular Interventions 8:165-173, (2008)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.8.4.8
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Walsh, C. T.
Right arrow Articles by Brown, J. H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walsh, C. T.
Right arrow Articles by Brown, J. H.
Reviews

G Protein-Coupled Receptors Go Extracellular: RhoA Integrates the Integrins

Colin T. Walsh1, Dwayne Stupack2 and Joan Heller Brown1

1 Department of Pharmacology and
2 Department of Pathology and The John and Rebecca Moores Cancer Center, University of California San Diego, La Jolla, CA 92093


Formula

The identification of downstream effectors of G protein–coupled receptors (GPCRs) is critical for understanding the interactions between signaling cascades and for developing new pharmacological approaches for controlling GPCR-mediated responses. RhoA is a small G protein that serves as a proximal downstream effector of numerous GPCRs and regulates a variety of basic cell functions, including migration, survival, and proliferation. Intriguingly, GPCR ligands such as thrombin, sphingosine-1-phosphate, and lysophosphatidic acid, which signal through G12/13 and activate RhoA, have recently been shown to induce the expression of the extracellular matrix protein Cyr61 (i.e., CCN1). Cyr61 is secreted and interacts with cell surface integrins to activate kinase and transcriptional cascades that are also known to contribute to cell migration, survival, and proliferation. The GPCR/RhoA/Cyr61/integrin pathway defines a novel convergence mechanism for integrating GPCR-and integrin-dependent signaling cascades that may contribute to sustained and pathophysiological responses to GPCR activation.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.